LDL apheresis improves deranged cardiovagal modulation in hypercholesterolemic patients

Atherosclerosis

Volumn 213, Issue 1, 2010, Pages 212-217

  Reimann, Manja ^a   Julius, Ulrich ^a   Haink, Kristin ^a   Lippold, Birgit ^a   Tselmin, Sergey ^a   Bornstein, Stefan R ^a   Reichmann, Heinz ^a   Rüdiger, Heinz ^a   Ziemssen, Tjalf ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

Autonomic nervous system; Baroreflex sensitivity; LDL apheresis; Trigonometric regressive spectral analysis

Indexed keywords

LOW DENSITY LIPOPROTEIN;

ADULT; APHERESIS; ARTICLE; AUTONOMIC NERVOUS SYSTEM; BLOOD PRESSURE; CARDIOVASCULAR AUTOREGULATION; CLINICAL ARTICLE; CONTROLLED STUDY; ELECTROCARDIOGRAM; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; MALE; PRESSORECEPTOR REFLEX; PRIORITY JOURNAL; RR INTERVAL; TREATMENT OUTCOME; VAGUS NERVE;

AGE FACTORS; AGED; AUTONOMIC NERVOUS SYSTEM; BAROREFLEX; BLOOD COMPONENT REMOVAL; BLOOD PRESSURE; CHOLESTEROL, LDL; ELECTROCARDIOGRAPHY; FEMALE; HEART RATE; HUMANS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; REGRESSION ANALYSIS;

EID: 77958485180     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.07.019     Document Type: Article

References (28)

1. Julius U., Frind A., Tselmin S., et al. Comparison of different LDL apheresis methods. Expert Rev Cardiovasc Ther 2008, 6:629-639.
2. Thompsen J., Thompson P.D. A systematic review of LDL apheresis in the treatment of cardiovascular disease. Atherosclerosis 2006, 189:31-38.
3. Rubba P., Faccenda F., Di Somma S., et al. Cerebral blood flow velocity and systemic vascular resistance after acute reduction of low-density lipoprotein in familial hypercholesterolemia. Stroke 1993, 24:1154-1161.
4. Tamai O., Matsuoka H., Itabe H., et al. Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. Circulation 1997, 95:76-82.
5. Wang Y., Blessing F., Walli A.K., et al. Effects of heparin-mediated extracorporeal low-density lipoprotein precipitation beyond lowering proatherogenic lipoproteins - reduction of circulating proinflammatory and procoagulatory markers. Atherosclerosis 2004, 175:145-150.
6. Reimann M., Prieur S., Lippold B., et al. Retinal vessel analysis in hypercholesterolemic patients before and after LDL apheresis. Atherosclerosis 2009, 10(Suppl.):39-43.
7. Mabuchi H., Koizumi J., Shimizu M., et al. Long-term efficacy of low-density lipoprotein apheresis on coronary heart disease in familial hypercholesterolemia. Hokuriku-FH-LDL-Apheresis Study Group. Am J Cardiol 1998, 82:1489-1495.
8. Matsuzaki M., Hiramori K., Imaizumi T., et al. Intravascular ultrasound evaluation of coronary plaque regression by low density lipoprotein-apheresis in familial hypercholesterolemia: the Low Density Lipoprotein-Apheresis Coronary Morphology and Reserve Trial (LACMART). J Am Coll Cardiol 2002, 40:220-227.
9. Walzl M., Lechner H., Walzl B., Schied G. Improved neurological recovery of cerebral infarctions after plasmapheretic reduction of lipids and fibrinogen. Stroke 1993, 24:1447-1451.
10. Blaha M., Cermanova M., Blaha V., et al. Safety and tolerability of long lasting LDL-apheresis in familial hyperlipoproteinemia. Ther Apher Dial 2007, 11:9-15.
11. Passauer J., Bussemaker E., Gross P. Dialysis hypotension: do we see light at the end of the tunnel?. Nephrol Dial Transplant 1998, 13:3024-3029.
12. Converse R.L., Jacobsen T.N., Jost C.M., et al. Paradoxical withdrawal of reflex vasoconstriction as a cause of hemodialysis-induced hypotension. J Clin Invest 1992, 90:1657-1665.
13. Weise F., London G.M., Pannier B.M., Guerin A.P., Elghozi J.L. Effect of hemodialysis on cardiovascular rhythms in end-stage renal failure. Kidney Int 1995, 47:1443-1452.
14. Tong Y.Q., Hou H.M. Alteration of heart rate variability parameters in nondiabetic hemodialysis patients. Am J Nephrol 2007, 27:63-69.
15. Consensus statement on the definition of orthostatic hypotension, pure autonomic failure, and multiple system atrophy. The Consensus Committee of the American Autonomic Society and the American Academy of Neurology. Neurology 1996;46:1470.
16. Laude D., Elghozi J.L., Girard A., et al. Comparison of various techniques used to estimate spontaneous baroreflex sensitivity (the EuroBaVar study). Am J Physiol Regul Integr Comp Physiol 2004, 286:R226-R231.
17. Ziemssen T., Gasch J., Ruediger H. Influence of ECG sampling frequency on spectral analysis of RR intervals and baroreflex sensitivity using the EUROBAVAR data set. J Clin Monit Comput 2008, 22:159-168.
18. Friedrich C., Rüdiger H., Schmidt C., Herting B., Prieur S., Junghanns S., Schweitzer K., Globas C., Schöls L., Berg D., Reichmann H., Ziemssen T. Baroreflex sensitivity and power spectral analysis during autonomic testing in different extrapyramidal syndromes. Mov Disord 2010, 25(3):315-324. .
19. Genovesi S., Bracchi O., Fabbrini P., et al. Differences in heart rate variability during haemodialysis and haemofiltration. Nephrol Dial Transplant 2007, 22:2256-2262.
20. Cavalcanti S., Severi S., Chiari L., et al. Autonomic nervous function during haemodialysis assessed by spectral analysis of heart-rate variability. Clin Sci (Lond) 1997, 92:351-359.
21. Severi S., Ciandrini A., Grandi E., et al. Cardiac response to hemodialysis with different cardiovascular tolerance: heart rate variability and QT interval analysis. Hemodial Int 2006, 10:287-293.
22. Mera K., Anraku M., Kitamura K., et al. The structure and function of oxidized albumin in hemodialysis patients: Its role in elevated oxidative stress via neutrophil burst. Biochem Biophys Res Commun 2005, 334:1322-1328.
23. Kopprasch S., Graessler J., Bornstein S.R., et al. Beyond lowering circulating LDL: apheresis-induced changes of systemic oxidative stress markers by four different techniques. Atheroscler 2009, 10(Suppl.):34-38.
24. Vonend O., Rump L.C., Ritz E. Sympathetic overactivity - the Cinderella of cardiovascular risk factors in dialysis patients. Semin Dial 2008, 21:326-330.
25. Kopprasch S., Graessler J., Bornstein S.R., et al. Beyond lowering circulationg LDL: apheresis-induced changes of systemic oxidative stress markers by four different techniques. Atherosclerosis 2009, 10(Suppl.):34-38.
26. Guggilam A., Haque M., Kerut E.K., et al. TNF-alpha blockade decreases oxidative stress in the paraventricular nucleus and attenuates sympathoexcitation in heart failure rats. Am J Physiol Heart Circ Physiol 2007, 293:H599-609.
27. Ye S., Zhong H., Yanamadala S., Campese V.M. Oxidative stress mediates the stimulation of sympathetic nerve activity in the phenol renal injury model of hypertension. Hypertension 2006, 48:309-315.
28. Tauseef M., Sharma K.K., Fahim M. Aspirin restores normal baroreflex function in hypercholesterolemic rats by its antioxidative action. Eur J Pharmacol 2007, 556:136-143.